Financhill
Back

Reata Pharmaceuticals Quote, Financials, Valuation and Earnings

Sell
29

RETA
Reata Pharmaceuticals

Last Price:
25.15
Seasonality Move:
0.48%

7 Day Trial

ALL ACCESS PASS

$ 7

Reata Pharmaceuticals Price Quote

$25.15
+0.02 (+0.48%)
(Updated: October 1, 2022 at 5:37 AM ET)

Reata Pharmaceuticals Key Stats

Sell
29
Reata Pharmaceuticals (RETA) is a Sell

Day range:
$24.68 - $25.95
52-week range:
$18.47 - $114.80
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
91.51
P/B ratio:
13.36%

Volume:
579.3K
Avg. volume:
973.7K
1-year change:
-75.02%
Market cap:
$917.2M
Revenue:
$11.5M
EPS:
$-8.37

How Much Does Reata Pharmaceuticals Make?

Is Reata Pharmaceuticals Growing As A Company?

  • What Is Reata Pharmaceuticals's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.66%
  • What Is Reata Pharmaceuticals's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Reata Pharmaceuticals Stock Price Performance

What Is Reata Pharmaceuticals 52-Week High & Low?

Reata Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Reata Pharmaceuticals?

Is Reata Pharmaceuticals Cash Flow Positive?

  • What Is RETA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$272.4M
  • What Is Reata Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $1.2M
  • What Is Reata Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$337.4M

Reata Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    RETA return on invested capital is -159.96%
  • What Is Reata Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -42.83%
  • What Is RETA Return On Equity?
    ROE is a measure of profitability and is -159.96%

Reata Pharmaceuticals Earnings Date & Stock Price

Reata Pharmaceuticals Competitors

Reata Pharmaceuticals Dividend Yield

Data Unavailable

Reata Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 29.53%
Revenue: -65.69% -47.9%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 50.67
Upside from Last Price: 101.62%

Major Shareholders

  • How many RETA shares are owned by institutional investors?
    42.2M RETA shares are owned by institutional investors
  • How many RETA shares are owned by insiders?
    413K RETA shares are owned by insiders